By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

130 Waverly Street

Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced

Key Statistics

Ownership: Public

Web Site: Vertex Pharmaceuticals (MA)
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
Vertex Pharmaceuticals (MA) (VRTX) To Announce Third Quarter 2014 Financial Results On October 28 10/15/2014 9:01:10 AM
Vertex Pharmaceuticals (MA) (VRTX) Reviews Recent Progress And Announces Upcoming Milestones In The Development Of Multiple Combinations Of Medicines That Target The Underlying Cause Of Cystic Fibrosis 10/9/2014 8:39:35 AM
Vertex Pharmaceuticals (MA) (VRTX) Announces Upcoming Presentations Of Data At North American Cystic Fibrosis Conference - October 9 To 11, 2014 9/8/2014 10:29:23 AM
Lung Biotech ProQR Therapeutics B.V. Files For A $75 Million IPO To Give Vertex Pharmaceuticals (MA) (VRTX) Some Competition 8/15/2014 7:04:08 AM
Vertex Pharmaceuticals (MA) (VRTX) To Stop Selling Once-Upon-A-Time Blockbuster Incivek, Shares Slip 8/12/2014 3:58:39 PM
Vertex Pharmaceuticals (MA) (VRTX)'s $300,000 A Year Drug Is Denied, And Medicaid Patients Sue 7/18/2014 7:42:11 AM
Vertex Pharmaceuticals (MA) (VRTX) To Announce Second Quarter 2014 Financial Results On July 29 7/15/2014 10:09:07 AM
Vertex Pharmaceuticals (MA) (VRTX) Announces Retirement Of Peter Mueller, Ph.D. 7/10/2014 11:19:15 AM
Vertex Pharmaceuticals (MA) (VRTX) Submits Supplemental New Drug Application (sNDA) To FDA For Use Of KALYDECO® (Ivacaftor) In People 18 And Older With Cystic Fibrosis Who Have The R117H Mutation 7/1/2014 11:06:08 AM
Vertex Pharmaceuticals (MA) (VRTX) Grabs EU Recommendation For KALYDECO™ (Ivacaftor) In Eight Non-G551D Gating Mutations 6/27/2014 6:20:08 AM